ERBB2
ERBB2 (erb-b2 receptor tyrosine kinase 2), also known as Human epidermal growth factor receptor 2 (HER2) (human EGFR 2), is a protein-coding gene that encodes a member of the ErbB family of receptor tyrosine kinases.
ERBB2 (erb-b2 receptor tyrosine kinase 2), also known as Human epidermal growth factor receptor 2 (HER2) (human EGFR 2), is a protein-coding gene that encodes a member of the ErbB family of receptor tyrosine kinases. The ERBB2 protein is a transmembrane receptor composed of an extracellular ligand-interaction region, a single membrane-spanning segment, and an intracellular tyrosine kinase domain. Unlike several related ErbB receptors, ERBB2 has no well-established high-affinity soluble ligand; it functions primarily as a preferred dimerization partner for ligand-activated receptors such as EGFR (ErbB1).
Dimerization activates ERBB2 kinase activity and promotes phosphorylation of intracellular Signaling proteins, including pathways involving RAS–MAPK and Phosphatidylinositol 3-kinase (PI3K)–Protein kinase B (PKB). These signals regulate cellular proliferation, survival, differentiation, migration, and tissue organization. Increased ERBB2 copy number or protein expression can produce persistent Signaling and is a clinically important molecular alteration in several Cancers, particularly breast cancer, as well as subsets of gastric, gastroesophageal, colorectal, lung, and other Tumors. ERBB2-directed therapies include monoclonal antibodies, antibody-drug conjugates, and small-molecule kinase inhibitors; the latter can inhibit ERBB2 alone or together with related receptors such as EGFR.
ERBB2 activity is influenced by interactions with the tumor microenvironment and with other oncogenic alterations, including changes involving PIK3CA, MET, MYC, and MDM2. Its expression or amplification may be evaluated using immunohistochemistry and fluorescence in situ hybridization, methods that distinguish increased protein abundance from increased gene copy number. ERBB2 Signaling has also been investigated beyond oncology, including in studies of respiratory syncytial virus and interleukin-17 family-associated processes.
- Zwitterionic Brush-Engineered Molecular Spherical Nucleic Acids for Enhanced Intracellular Antisense Activity. PMID 42715048
Where the papers sit
12 papers study erbb2 directly. Those 12 do not group into themes. No shared biological question or direction emerges; topics range from antisense delivery and cancer profiling to targeted radiotherapy and antiviral drug screening. They are no more alike than papers drawn from anywhere in the corpus. 1 new direction follows.
ERBB2 inhibition is presented as an antiviral strategy against respiratory syncytial virus
The respiratory syncytial virus infection model in A549 cells and BALB/c mice treats ERBB2 not as a tumor biomarker or cancer-therapy target, but as part of a host pathway governing viral disease. Lapatinib, proposed to act through ErbB1 and ErbB2, suppressed RSV replication and inflammatory lung injury by downregulating IL-17, while IL-17 overexpression antagonized the effect. This gives ERBB2 a distinct antiviral and immunomodulatory role and points to lapatinib-mediated ErbB2 blockade as a possible treatment direction for RSV infection 42376990Jun.
Recent Findings on ERBB2
Unrelated Molecular Studies: ERBB2 studies now span antisense delivery, molecular profiling, precision oncology, targeted radiotherapy, immunotherapy, and antiviral drug screening. Nuclear HER2/ErbB3 co-expression marked higher Fuhrman Nuclear Grade and advanced stage in clear cell renal cell carcinoma, whereas ERBB2 amplification accompanied a distinct SMARCA2/4-deficient esophageal adenocarcinoma subtype; one lung adenocarcinoma case showed sequential clinical benefit after identifying HER2 amplification and EGFR L858R 42674699Aug42527418Jul42681853Sep. Therapeutic approaches include zwitterionic brush-engineered molecular spherical nucleic acids, [47Sc]Sc-NOTA-trastuzumab, HER2 ECD mRNA-LNP vaccines, NH2-trimethyl lock antibody-drug conjugates, quinazolinone dual EGFR/HER-2 inhibitors, and trastuzumab deruxtecan for EGFR S442 mutation-mediated cetuximab resistance 42715048Sep42480146Jul42378880Jun42218895May42217499May42176792May. These interventions produced encouraging preclinical or case-level responses, but their mechanisms and predictive markers differ across HER2 amplification, activating HER2 mutations, receptor trafficking, immune activation, and EGFR–ERBB2 interaction 42423636Jul42681853Sep42176792May. Diagnostic development is moving toward multiplex profiling of circulating exosomes using HER2, Mucin 1, and CD44, while lapatinib also showed anti-RSV activity through ErbB1/ErbB2-associated suppression of the IL-17 pathway 42410964Jul42376990Jun.
Written from 12 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.